- Artemis Therapeutics is a biopharmaceutical company developing new treatments for serious and life-threatening infections, including cytomegalovirus and malaria.
- Congenital CMV is more common in the U.S. than Zika, SIDS, or Fetal Alcohol Syndrome, yet 9 out of 10 people are not familiar with it (Centers for Disease Control and Prevention).
- Malaria kills more than 400,000 people per year, mostly children, with enormous economic, social, and humanitarian impact.
The company’s lead product candidate is a potent antiparasitic drug called Artemisone. It was originally developed through a collaboration between Bayer HealthCare AG and the Hong Kong University of Science and Technology. Artemisone has been studied in multiple Phase 1 clinical trials and a 95-patient Phase 2 clinical trial as a treatment for malaria. A subsequent discovery of Artemisone as an antiviral was patented by Hadassah Medical Center in Israel and licensed to Artemis in 2016. Based on preliminary clinical results with a related compound, Artemisone is currently undergoing preclinical evaluation of its activity against cytomegalovirus (CMV), to assess its potential for both immunocompromised and congenital CMV patients.
Completed Clinical Trials
Artemisone for Malaria
Phase 2 – Safety and efficacy (n=95)
Phase 1 – Multiple-ascending dose (n=24)
Phase 1 – Single-ascending dose (n=32)
Phase 1 – Bioavailability (n=12)
|Preclinical||Phase 1||Phase 2||Phase 3|
Artemisone for Cytomegalovirus (CMV)
Preclincal (IND preparations ongoing)
|Preclinical||Phase 1||Phase 2||Phase 3|
Brian Culley, MBA
Chief Executive Officer
Read Brian’s Bio...
Prior to Artemis, Mr. Culley served as Chief Executive Officer and member of the Board of Directors of Mast Therapeutics (NYSEMKT:MSTX) until its 2017 merger with Savara, Inc. (NASDAQ:SVRA). Mr. Culley served previously as Mast’s Chief Business Officer and Head of Business Development. From 2002-2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999-2000, he worked at the University of California, San Diego (UCSD) Technology Transfer Office. From 1996-1999 he conducted drug discovery research for Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Mr. Culley received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.
Dana Wolf, MD, PhD
Chief Medical Officer
Read Dana’s Bio...
Dr. Wolf is a Professor of Virology and Infectious Diseases at the Hebrew University and Director of the Clinical Virology Unit at the Hadassah Medical Center, Jerusalem. She received her M.D. at the Hebrew University Hadassah Medical School and completed her Internal Medicine residency and fellowship in Infectious Diseases at the Hadassah Medical Center. She pursued a postdoctoral fellowship in Virology at the University of California San Diego and spent a year as a visiting scientist at Stanford University. Dr. Wolf studies human cytomegalovirus transmission and pathogenesis, employing a unique ex vivo placental model to characterize the mode of maternal-to-fetal viral transmission. Her lab focuses on the discovery and evaluation of novel antiviral drugs and the mechanism of CMV drug resistance. Dr. Wolf is a member of several national and international advisory committees and boards.
Chief Financial Officer
Read Chanan’s Bio...
Chanan Morris has been the Chief Financial Officer of Artemis Therapeutics since its inception in April 2016. He previously served as the Chief Financial Officer of New York Global Innovations Inc. Mr. Morris has also served as the CFO of Galmed (NASDAQ:GLMD) and completed an IPO on the Nasdaq stock exchange. Prior to that Mr. Morris also served as the CFO of Surpass Medical Ltd during its acquisition by Stryker Corporation (NYSE:SYK) which was successfully completed in 2012. Mr. Morris is currently a director at the Infinity Group and serves as a board member of several of its Companies in the United States and China as well as serving as Vice President of Finance & Operations for some of the Groups’ companies including Mango DSP Ltd and its subsidiaries. Mr. Morris received his B.Sc. in Accounting from Northeastern University.
- Michael Boeckh, MD, PhD
- Michael Cordingley, PhD
- Richard Haynes, PhD
- Amit Limaye, MD
- Peter Payne
- Steven Spector, MD